Table 1 Baseline demographics and clinical characteristics (ITT population: TP3)
Biosimilar (n = 259) | Week 26 switch (n = 127) | Week 52 switch (n = 121) | Total (N = 507) | |
|---|---|---|---|---|
Female, n (%) | 210 (81.1) | 88 (69.3) | 98 (81.0) | 396 (78.1) |
Age, years | 51.1 (13.8) | 53.1 (13.5) | 53.1 (11.7) | 52.1 (13.3) |
Weight, kg | 74.9 (18.0) | 74.6 (17.7) | 77.2 (21.2) | 75.4 (18.7) |
BMI, kg/m2 | 27.6 (6.3) | 27.1 (5.8) | 28.8 (7.6) | 27.8 (6.5) |
Race, n (%) | ||||
White | 230 (88.8) | 109 (85.8) | 100 (82.6) | 439 (86.6) |
Black | 5 (1.9) | 2 (1.6) | 7 (5.8) | 14 (2.8) |
Asian | 11 (4.2) | 6 (4.7) | 7 (5.8) | 24 (4.7) |
Other | 13 (5.0) | 10 (7.9) | 7 (5.8) | 30 (5.9) |
Ethnicity, n (%) | ||||
Not Hispanic/Latino | 236 (91.1) | 117 (92.1) | 108 (89.3) | 461 (90.9) |
RA duration, years | 6.8 (7.2) | 6.5 (7.0) | 7.0 (6.6) | 6.8 (7.0) |
RF or anti-CCP antibody positive, n (%) | 208 (80.3) | 102 (80.3) | 105 (86.8) | 415 (81.9) |
Swollen joint count | 15.0 (7.6) | 16.8 (10.1) | 17.3 (9.8) | 16.0 (8.9) |
Tender joint count | 23.8 (11.9) | 25.4 (14.8) | 26.5 (15.0) | 24.9 (13.5) |
hs-CRP, mg/L | 20.4 (20.4) | 22.7 (26.5) | 22.3 (25.3) | 21.4 (23.3) |
MTX dose, mg/week | 15.3 (4.4) | 14.6 (4.1) | 15.8 (4.6) | 15.2 (4.4) |
Corticosteroid use, n (%) | 145 (56.0) | 79 (62.2) | 68 (56.2) | 292 (57.6) |